Is it just me....
Or did anyone notice the difference between august press release and this one. Specifically about the company.
Very interesting difference. I think the key is the details about AVAX, plus looks like it was approved for phase 3? some other goodies between the two updates.
August:
AVAX Technologies, Inc. is a Philadelphia based biotechnology company engaged in the research, clinical and commercial development of biological products and cancer therapeutics. AVAX’s AC Vaccine platform is a therapeutic cancer vaccine. AVAX previously submitted a protocol for its planned Phase 3 pivotal registration trial of M-Vax, its AC Vaccine® product candidate for the treatment of Melanoma. AVAX has met with the United States Food and Drug Administration (“FDA”) on the study design and has plans to continue to work with FDA to be able to focus and re-launch this pivotal clinical study. The company completed enrollment of its Phase 1/2 Trial for O-Vax, its AC Vaccine® product candidate for the treatment of Ovarian Cancer. Early results from this promising clinical study were presented at the Society of Gynecologic Oncology’s 19th Annual Winter Meeting, which AVAX announced in January 14, 2014. The Company plans to obtain all of the follow-up data and meet with the FDA to discuss further clinical development plans regarding this program.
October:
AVAX's core technology platform, termed, Autologous Cell ("AC") Vaccine Technology is a universal platform approach to individualized cancer vaccine therapy. AVAX has 2 vaccines that have completed phase 2 clinical trials, both designated with Orphan Drug Status. M-Vax is a post-surgical autologous cell vaccine for melanoma, which was approved to enter a Phase III-REGISTRATION trial for the treatment of Stage 4 melanoma patients with measurable metastasis. O-Vax - is AVAX's post-surgical autologous cell vaccine for Stage 3 & 4 ovarian cancer. The O-Vax trial is a phase I/II trial that has completed enrollment and is in the process of gathering follow-up data on all patients. This data will be submitted to FDA when complete and will be used to file an application in support of a follow-on phase II or phase III trial. In addition, the Company's pipeline includes a second generation autologous vaccine, developed by the inventor of MVax and OVax. Finally, the Company has an extensive bio-bank of lymphocytes and tumor cells from AC Vaccine-treated patients that may be of commercial interest as a key to identifying new human cancer antigens.
